摘要
Abstract
Objective:To investigate the clinical effect of Montelukast Sodium combined with Bifidobacterium,Lactobacillus,Enterococcus and Bacillus Cereus in the treatment of children with abdominal allergic purpura.Method:A total of 150 children with abdominal allergic purpura treated in Suqian First People's Hospital from May 2021 to May 2024 were selected as the study objects,and they were divided into control group and experimental group by random number table method,with 75 cases in each group.The two groups received liquid rehydration,anti-allergy,anti-platelet aggregation and other basic treatment,the control group was given Montelukast Sodium treatment,the experimental group was given Montelukast Sodium combined with Bifidobacterium,Lactobacillus,Enterococcus and Bacillus Cereus treatment.Both groups were treated for 1 month.The changes of intestinal flora[lactobacillus(LAC),bifidobacterium(BIF),enterobacterium(ENT),enterococcus(EC)],immune function indexes[immunoglobulin A(IgA),immunoglobulin G(IgG),immunoglobulin M(IgM)],kidney injury indexes[insulin-like growth factor-1(IGF-1),soluble human stromal lysin(sST2),transforming growth factor-β1(TGF-β1)]in the two groups were compared,and the total effective rate and incidence of adverse reactions between the two groups were compared.Result:After treatment,LAC and BIF in experimental group were higher than those in control group,ENT and EC were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,the levels of IgA,IgG and IgM in experimental group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,the levels of IGF-1,sST2 and TGF-β1 in experimental group were lower than those in control group,the differences were statistically significant(P<0.05).The total effective rate of experimental group was higher than that of control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:For children with abdominal allergic purpura,Montelukast Sodium combined with Bifidobacterium,Lactobacillus,Enterococcus and Bacillus Cereus treated in combination with basic treatment can improve the intestinal immune environment,regulate the number of beneficial and harmful bacteria in the intestine,improve the therapeutic effect,and the combined program can reduce kidney injury without increasing the incidence of adverse reactions.关键词
儿童腹型过敏性紫癜/孟鲁司特钠/双歧杆菌四联活菌Key words
Children with abdominal allergic purpura/Montelukast Sodium/Bifidobacterium,Lactobacillus,Enterococcus and Bacillus Cereus
